Bierhoff E, Szeimies R-M, Reinhold U, Dirschka T
MVZ Corius DermPathBonn GmbH, Heinz-Werner-Seifert-Institute of Dermatopathology Bonn, Germany.
Department of Dermatology and Allergology, Klinikum Vest GmbH, Recklinghausen, Germany.
Photodiagnosis Photodyn Ther. 2024 Dec;50:104361. doi: 10.1016/j.pdpdt.2024.104361. Epub 2024 Oct 9.
Primary endpoints of clinical studies investigating treatments for actinic keratosis (AK) are mainly based on clinical evaluation, but a recent study showed that in AK, clinical classification according to Olsen and the extent of keratinocyte atypia do not necessarily correlate. The influence of the epidermal extent of atypia on treatment efficacy is usually not investigated and therefore remains largely unknown.
To evaluate whether the extent of keratinocyte atypia influences efficacy of photodynamic therapy (PDT) when treating AK.
We performed a post-hoc analysis of histological (keratinocyte intraepithelial neoplasia (KIN)), and clinical (Olsen) data of biopsied lesions of three pivotal studies evaluating PDT using 10 % aminolevulinic acid (ALA) gel or vehicle and narrow- or broad-spectrum red light lamps.
Overall, 514 biopsied lesions were considered. Clearance rates after red light PDT with 10 % ALA gel were comparable for KIN I-III (88.2 %, 92.0 % and 87.9 %) and Olsen I-II lesions for any given lamp type. Generally, clearance rates were higher using narrow- compared to broad-spectrum lamps. For both lamp types, the variation in clearance rates from KIN I-III was low. Clearance was lower with vehicle.
Varying lesion numbers in the subgroups and a remaining risk of bias due to the biopsies are potential limitations.
Our results suggest that red light PDT with 10 % ALA gel is an effective treatment option for AK regardless of the extent of keratinocyte atypia.
研究光化性角化病(AK)治疗方法的临床研究的主要终点主要基于临床评估,但最近一项研究表明,在AK中,根据奥尔森分类法进行的临床分类与角质形成细胞异型性程度不一定相关。异型性在表皮中的范围对治疗效果的影响通常未被研究,因此在很大程度上仍然未知。
评估角质形成细胞异型性程度在治疗AK时是否会影响光动力疗法(PDT)的疗效。
我们对三项关键研究中活检病变的组织学(角质形成细胞上皮内瘤变(KIN))和临床(奥尔森)数据进行了事后分析,这三项研究评估了使用10%氨基酮戊酸(ALA)凝胶或赋形剂以及窄谱或宽谱红灯进行的PDT。
总体而言,共考虑了514个活检病变。对于任何给定的灯型,KIN I - III(88.2%、92.0%和87.9%)以及奥尔森I - II级病变在使用10% ALA凝胶进行红光PDT后的清除率相当。一般来说,使用窄谱灯时的清除率高于宽谱灯。对于两种灯型,KIN I - III级病变清除率的变化都很小。使用赋形剂时清除率较低。
亚组中病变数量不同以及活检存在残留偏倚风险是潜在的局限性。
我们的结果表明,无论角质形成细胞异型性程度如何,使用10% ALA凝胶进行红光PDT都是治疗AK的有效选择。